Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5988) 5988
Publication (749) 749
Newsletter (362) 362
Book Review (98) 98
Magazine Article (51) 51
Newspaper Article (35) 35
Book Chapter (34) 34
Conference Proceeding (12) 12
Dissertation (8) 8
Web Resource (6) 6
Reference (4) 4
Trade Publication Article (3) 3
Book / eBook (2) 2
Streaming Video (2) 2
Data Set (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3916) 3916
bupropion (3654) 3654
male (2290) 2290
female (2077) 2077
index medicus (2044) 2044
adult (1734) 1734
bupropion - therapeutic use (1567) 1567
psychiatry (1441) 1441
smoking cessation (1340) 1340
middle aged (1324) 1324
pharmacology & pharmacy (1271) 1271
smoking cessation - methods (1234) 1234
sustained-release bupropion (1093) 1093
smoking (954) 954
treatment outcome (897) 897
varenicline (854) 854
nicotine (703) 703
smoking cessation programs (692) 692
animals (640) 640
bupropion - adverse effects (633) 633
antidepressants (574) 574
bupropion - administration & dosage (571) 571
double-blind (562) 562
neurosciences (555) 555
research (555) 555
receptor partial agonist (554) 554
depression (546) 546
drug therapy (542) 542
antidepressive agents, second-generation - therapeutic use (539) 539
substance abuse (537) 537
aged (536) 536
adolescent (530) 530
smoking-cessation (525) 525
cessation (517) 517
medicine, general & internal (506) 506
article (488) 488
placebo (484) 484
randomized controlled-trial (481) 481
double-blind method (477) 477
nicotine replacement therapy (471) 471
pharmacotherapy (454) 454
dopamine uptake inhibitors - therapeutic use (447) 447
bupropion - pharmacology (445) 445
smokers (443) 443
tobacco (440) 440
care and treatment (426) 426
antidepressive agents - therapeutic use (401) 401
efficacy (392) 392
nicotinic agonists - therapeutic use (383) 383
smoking prevention (378) 378
risk factors (375) 375
analysis (370) 370
cigarette-smoking (367) 367
tobacco use disorder - drug therapy (365) 365
dose-response relationship, drug (363) 363
rats (355) 355
health aspects (353) 353
nicotine - administration & dosage (350) 350
psychology, clinical (337) 337
drugs (336) 336
depressive disorder - drug therapy (335) 335
young adult (334) 334
drug therapy, combination (326) 326
clinical neurology (325) 325
public, environmental & occupational health (323) 323
benzazepines - therapeutic use (315) 315
dependence (313) 313
dopamine (312) 312
nicotine - therapeutic use (305) 305
placebo-controlled trial (298) 298
quinoxalines - therapeutic use (296) 296
antidepressive agents, second-generation - adverse effects (289) 289
smoking - drug therapy (286) 286
smoking cessation - psychology (275) 275
usa (275) 275
clinical trials (272) 272
delayed-action preparations (264) 264
dosage and administration (260) 260
nicotine dependence (259) 259
major depression (251) 251
depressive disorder, major - drug therapy (244) 244
smoking - epidemiology (237) 237
depression, mental (234) 234
smoking - psychology (234) 234
time factors (233) 233
fluoxetine (232) 232
drug interactions (229) 229
comorbidity (227) 227
therapy (225) 225
follow-up studies (222) 222
medicine & public health (220) 220
antidepressant (219) 219
mental disorders (217) 217
antidepressive agents - adverse effects (215) 215
abridged index medicus (214) 214
usage (212) 212
randomized controlled trials as topic (211) 211
counseling (207) 207
major depressive disorder (207) 207
pharmacology (206) 206
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6069) 6069
Spanish (112) 112
German (93) 93
French (71) 71
Turkish (24) 24
Polish (17) 17
Portuguese (16) 16
Korean (10) 10
Dutch (9) 9
Italian (8) 8
Japanese (8) 8
Czech (7) 7
Danish (7) 7
Norwegian (7) 7
Chinese (5) 5
Hungarian (4) 4
Russian (4) 4
Swedish (4) 4
Hebrew (2) 2
Persian (2) 2
Finnish (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Complex Modulation of the GABA.sub.A [alpha]1[beta]2[gamma]2 Receptor Function by Bupropion
by Thompson, Jeremy M and Pappu, Aneesh and Pandhare, Akash and Jansen, Michaela
Biophysical Journal, ISSN 0006-3495, 01/2015, Volume 108, Issue 2, p. 433
Bupropion
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Intravenous abuse of bupropione/Intravenoser Missbrauch von Bupropion
by Behler, N and Lehmann, A and Malchow, B and Palm, U
Der Nervenarzt, ISSN 0028-2804, 11/2017, Volume 88, Issue 11, p. 1320
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00115-016-0200-3 
Bupropion
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Bupropion exposure in an infant
by Colantonio, D and Delaney, S and Neuman, G and Ito, S
Clinical Biochemistry, ISSN 0009-9120, 06/2014, Volume 47, Issue 9, pp. 769 - 769
Bupropion
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Intranasal Bupropion Abuse
The American Journal on Addictions, ISSN 1055-0496, 03/2013, Volume 22, Issue 2, p. 180
Bupropion
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Bupropion and Bupropion Analogs as Treatments for CNS Disorders
by Carroll, F. Ivy and Blough, Bruce E and Mascarella, S. Wayne and Navarro, Hernán A and Lukas, Ronald J and Damaj, M. Imad
2014, ISBN 9780124201187, Volume 69
Bupropion, introduced as an antidepressant in the 1980s, is also effective as a smoking cessation aid and is beneficial in the treatment of methamphetamine... 
Smoking cessation | Antidepressants | Bupropion and bupropion analogs | Hydroxybupropion | Nicotinic receptor antagonists | Dopamine and norepinephrine uptake inhibitors | Bupropion/nAChR binding | Bupropion analogs for nicotine addiction | Animals | Bupropion - chemistry | Humans | Central Nervous System Diseases - drug therapy | Bupropion - analogs & derivatives | Treatment Outcome | Central Nervous System Diseases - metabolism | Bupropion - therapeutic use | Protein Binding - physiology
Book Chapter
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Bupropion: A Review of its Use in the Management of Major Depressive Disorder
by Dhillon, Sohita and Yang, Lily P.H and Curran, Monique P
Drugs, ISSN 0012-6667, 2008, Volume 68, Issue 5, pp. 653 - 689
Bupropion is presumed to be a dopamine-norepinephrine reuptake inhibitor and is an effective antidepressant. It is available as three oral formulations: (i)... 
Depression | Adis Drug Evaluations | Bupropion | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Bupropion, general | ATOPIC-DERMATITIS | SEROTONIN-REUPTAKE INHIBITORS | ANTIDEPRESSANT EFFICACY | HEALTHY-SUBJECTS | OUTPATIENTS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | NECROSIS-FACTOR-ALPHA | TOXICOLOGY | SUSTAINED-RELEASE BUPROPION | DOPAMINE TRANSPORTER | REM-SLEEP | Bupropion - pharmacokinetics | Humans | Serotonin Uptake Inhibitors - therapeutic use | Body Weight - drug effects | Citalopram - therapeutic use | Antidepressive Agents, Second-Generation - therapeutic use | Bupropion - adverse effects | Delayed-Action Preparations | Bupropion - administration & dosage | Bupropion - therapeutic use | Depressive Disorder, Major - drug therapy | Randomized Controlled Trials as Topic | Usage | Drug therapy | Antidepressants | Health aspects | Major depressive disorder
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Geneva Cocktail for Cytochrome P450 and P‐Glycoprotein Activity Assessment Using Dried Blood Spots
by Bosilkovska, M and Samer, C F and Déglon, J and Rebsamen, M and Staub, C and Dayer, P and Walder, B and Desmeules, J A and Daali, Y
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2014, Volume 96, Issue 3, pp. 349 - 359
The suitability of the capillary dried blood spot (DBS) sampling method was assessed for simultaneous phenotyping of cytochrome P450 (CYP) enzymes and... 
P4502B6 ACTIVITY | VORICONAZOLE | LC-MS/MS | SINGLE-POINT | ORAL MIDAZOLAM | VOLUNTEERS | IN-VIVO | PHARMACOLOGY & PHARMACY | DRUG-METABOLIZING-ENZYMES | KAROLINSKA COCKTAIL | BUPROPION HYDROXYLATION | Predictive Value of Tests | Pharmaceutical Preparations - blood | Caffeine - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Dried Blood Spot Testing | Humans | Omeprazole - blood | Bupropion - blood | Midazolam - administration & dosage | Substrate Specificity | Male | Chromatography, High Pressure Liquid | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Coffee | Terfenadine - administration & dosage | Caffeine - pharmacokinetics | Feasibility Studies | Enzyme Inhibitors - administration & dosage | Young Adult | Chromatography, Reverse-Phase | Tandem Mass Spectrometry | Capsules | Spectrometry, Mass, Electrospray Ionization | Flurbiprofen - administration & dosage | Adult | Dextromethorphan - pharmacokinetics | Terfenadine - blood | ATP-Binding Cassette, Sub-Family B, Member 1 - blood | Pharmaceutical Preparations - administration & dosage | Terfenadine - pharmacokinetics | Bupropion - pharmacokinetics | Flurbiprofen - pharmacokinetics | Cytochrome P-450 Enzyme System - blood | Administration, Oral | Isoenzymes | Caffeine - blood | Omeprazole - administration & dosage | Terfenadine - analogs & derivatives | Omeprazole - pharmacokinetics | Carbonated Beverages | Midazolam - pharmacokinetics | Bupropion - administration & dosage | Dextromethorphan - blood | Flurbiprofen - blood | Phenotype | Pilot Projects | Midazolam - blood | Dextromethorphan - administration & dosage | Usage | Glycoproteins | Liquid chromatography | Research | Pharmacokinetics | Cytochrome P-450 | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A simple and sensitive LC–ESI-MS (ion trap) method for the determination of bupropion and its major metabolite, hydroxybupropion in rat plasma and brain microdialysates
by Yeniceli, Duygu and Şener, Erol and Korkmaz, Orhan Tansel and Doğrukol-Ak, Dilek and Tuncel, Neşe
Talanta, ISSN 0039-9140, 2011, Volume 84, Issue 1, pp. 19 - 26
A specific and highly sensitive liquid chromatography–electrospray mass spectrometry (LC–ESI-MS) method for the direct determination of bupropion (BUP) and its... 
LC–ESI-MS (ion trap) | Bupropion | Microdialysis | Hydroxybupropion | Rat plasma | LC-ESI-MS (ion trap) | EXTRACELLULAR DOPAMINE | SMOKING-CESSATION | CHEMISTRY, ANALYTICAL | MAIN METABOLITE | TANDEM MASS-SPECTROMETRY | HYDROCHLORIDE | LIQUID-CHROMATOGRAPHY | PHARMACOKINETICS | IN-VIVO | SEPARATION | SUSTAINED-RELEASE BUPROPION | Blood Chemical Analysis - methods | Bupropion - metabolism | Bupropion - pharmacokinetics | Brain - cytology | Reproducibility of Results | Bupropion - blood | Bupropion - analogs & derivatives | Rats | Linear Models | Male | Rats, Sprague-Dawley | Animals | Time Factors | Spectrometry, Mass, Electrospray Ionization - methods | Bupropion - analysis | Chromatography, Liquid - methods | Nitriles | Metabolites | Rain and rainfall | Mass spectrometry | Methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Chiral plasma pharmacokinetics and urinary excretion of bupropion and metabolites in healthy volunteers
by Masters, Andrea R and Gufford, Brandon T and Li Lu, Jessica Bo and Metzger, Ingrid F and Jones, David R and Desta, Zeruesenay
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 08/2016, Volume 358, Issue 2, pp. 230 - 238
Bupropion, widely used as an antidepressant and smoking cessation aid, undergoes complex metabolism to yield numerous metabolites with unique disposition,... 
SMOKING-CESSATION | IN-VITRO | DRUG INTERACTIONS | ANTIDEPRESSANT | CYP2B6 GENOTYPE | HYDROXYLATION | PHARMACOLOGY & PHARMACY | CYTOCHROME P4502B6 ACTIVITY | STEADY-STATE | LIVER-MICROSOMES | SUSTAINED-RELEASE BUPROPION | Bupropion - pharmacokinetics | Stereoisomerism | Humans | Middle Aged | Bupropion - blood | Male | Healthy Volunteers | Bupropion - urine | Young Adult | Bupropion - chemistry | Adult | Female | Aged | Metabolism, Transport, and Pharmacogenomics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Nicotine receptor partial agonists for smoking cessation
by Cahill, Kate and Lindson-Hawley, Nicola and Thomas, Kyla H and Fanshawe, Thomas R and Lancaster, Tim
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2016, Volume 2016, Issue 5, p. CD006103
Background Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract... 
Smoking [drug therapy] | Varenicline | Humans | RANDOMIZED CONTROLLED-TRIAL | Quinolizines [therapeutic use] | PSYCHIATRIC ADVERSE EVENTS | TOBACCO-DEPENDENCE TREATMENT | Quinoxalines [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Bupropion [therapeutic use] | Nicotine [adverse effects; antagonists & inhibitors] | REPLACEMENT THERAPY | SUSTAINED-RELEASE BUPROPION | Smoking Cessation [methods] | Counseling [methods] | VARENICLINE TREATMENT | METHADONE-MAINTAINED SMOKERS | Randomized Controlled Trials as Topic | Azepines [therapeutic use] | DOUBLE-BLIND PLACEBO | Alkaloids [therapeutic use] | Nicotinic Agonists [adverse effects; therapeutic use] | Azocines [therapeutic use] | LONG-TERM SAFETY | Benzazepines [therapeutic use] | PLACEBO-CONTROLLED TRIAL | Substance Withdrawal Syndrome [prevention & control] | Heterocyclic Compounds with 4 or More Rings [therapeutic use] | Quinolizines - therapeutic use | Azepines - adverse effects | Azocines - therapeutic use | Azocines - adverse effects | Substance Withdrawal Syndrome - prevention & control | Alkaloids - adverse effects | Benzazepines - adverse effects | Smoking - drug therapy | Heterocyclic Compounds, 4 or More Rings - adverse effects | Nicotinic Agonists - therapeutic use | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Azepines - therapeutic use | Nicotine - adverse effects | Nicotinic Agonists - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Benzazepines - therapeutic use | Counseling - methods | Alkaloids - therapeutic use | Quinolizines - adverse effects | Varenicline - therapeutic use | Bupropion - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies: A Network Meta-Analysis
by Mills, Edward J and Thorlund, Kristian and Eapen, Shawn and Wu, Ping and Prochaska, Judith J
Circulation, ISSN 0009-7322, 01/2014, Volume 129, Issue 1, pp. 28 - 41
BACKGROUND—Stopping smoking is associated with many important improvements in health and quality of life. The use of cessation medications is recommended to... 
varenicline | meta-analysis | cardiovascular diseases | tobacco use cessation products | smoking cessation | bupropion | CARDIAC & CARDIOVASCULAR SYSTEMS | NASAL SPRAY | RANDOMIZED CONTROLLED-TRIAL | NICOTINE-REPLACEMENT THERAPY | RECEPTOR PARTIAL AGONIST | CONTROLLED CLINICAL-TRIAL | DOUBLE-BLIND TRIAL | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | TRANSDERMAL NICOTINE | SUSTAINED-RELEASE BUPROPION | Quinoxalines - adverse effects | Nicotine - administration & dosage | Dopamine Uptake Inhibitors - adverse effects | Quinoxalines - administration & dosage | Benzazepines - adverse effects | Humans | Risk Factors | Varenicline | Smoking - drug therapy | Male | Smoking Cessation - statistics & numerical data | Smoking Cessation - methods | Bupropion - administration & dosage | Dopamine Uptake Inhibitors - administration & dosage | Nicotine - adverse effects | Nicotinic Agonists - adverse effects | Nicotinic Agonists - administration & dosage | Smoking - epidemiology | Cardiovascular Diseases - epidemiology | Adult | Female | Benzazepines - administration & dosage | Bupropion - adverse effects | Pharmacology | Research | Cardiovascular emergencies | Smoking cessation products | Methods | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion
by Laib, Anne K and Brünen, Sonja and Pfeifer, Philippe and Vincent, Philippe and Hiemke, Christoph
Therapeutic Drug Monitoring, ISSN 0163-4356, 2014, Volume 36, Issue 4, pp. 473 - 479
Background: Bupropion is a dopamine and norepinephrine reuptake inhibitor approved for the treatment of depression and smoking cessation. According to the... 
Gender differences | Bupropion | 4-hydroxybupropion | Therapeutic reference range | METABOLITES | HYDROXYLATION | MECHANISMS | RELEASE | gender differences | PROFILE | PLASMA | PHARMACOKINETICS | GENDER | PHARMACOLOGY & PHARMACY | TOXICOLOGY | MEDICAL LABORATORY TECHNOLOGY | bupropion | therapeutic reference range | ATYPICAL ANTIDEPRESSANTS | CYTOCHROME P4502B6 | Bupropion - metabolism | Antidepressive Agents, Second-Generation - pharmacokinetics | Bupropion - pharmacokinetics | Chromatography, High Pressure Liquid - methods | Area Under Curve | Humans | Middle Aged | Bupropion - blood | Bupropion - analogs & derivatives | Half-Life | Depressive Disorder - drug therapy | Male | Antidepressive Agents, Second-Generation - therapeutic use | Female | Retrospective Studies | Antidepressive Agents, Second-Generation - metabolism | Bupropion - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Combination therapy of varenicline and bupropion in smoking cessation: A meta-analysis of the randomized controlled trials
by Zhong, Zhaoshuang and Zhao, Shijie and Zhao, Yan and Xia, Shuyue
Comprehensive Psychiatry, ISSN 0010-440X, 09/2019, p. 152125
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Interventions for smoking cessation and reduction in individuals with schizophrenia
by Tsoi, Daniel T and Tsoi, Daniel T and Porwal, Mamta and Porwal, Mamta and Webster, Angela C and Webster, Angela C
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2013, Volume 2, Issue 12, p. CD007253
Background Individuals with schizophrenia smoke more heavily than the general population and this contributes to their higher morbidity and mortality from... 
Humans | Reinforcement (Psychology) | Schizophrenia | Nicotine [administration & dosage] | SCHIZOAFFECTIVE DISORDER | VARENICLINE TREATMENT | RANDOMIZED CONTROLLED-TRIAL | Schizophrenic Psychology | Antidepressive Agents, Second-Generation [therapeutic use] | Smoking [prevention & control] | MEDICINE, GENERAL & INTERNAL | CIGARETTE-SMOKING | TRANSCRANIAL MAGNETIC STIMULATION | Bupropion [therapeutic use] | Nicotinic Agonists [administration & dosage] | DOUBLE-BLIND | Adult | PLACEBO-CONTROLLED TRIAL | TRANSDERMAL NICOTINE | SUSTAINED-RELEASE BUPROPION | ANTIPSYCHOTIC MEDICATIONS | Smoking Cessation [methods] | Nicotine - administration & dosage | Tobacco Use Cessation Devices | Varenicline | Antidepressive Agents, Second-Generation - therapeutic use | Nicotinic Agonists - therapeutic use | Smoking Cessation - methods | Smoking Prevention | Randomized Controlled Trials as Topic | Benzazepines - therapeutic use | Bupropion - therapeutic use | Quinoxalines - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights